Missing a follow-up vaccination can leave protection incomplete. VitriVax, a vaccine developer in Boulder, Colorado, wants to make vaccination simpler with a technology designed to deliver protection in a single dose. It has raised $87 million to move its experimental Lyme disease vaccine into its first human trial and develop additional vaccines.
The company is shifting from supplying vaccine technology to developing medicines of its own. Its platform is also designed to keep vaccine ingredients stable, reducing dependence on refrigerated storage. That could help with both completing vaccination and reaching places where cooling is difficult. The immediate test is whether the Lyme vaccine produces the human data needed to support the company's ambitions.
Source · vitrivaxbio.com ↗
